Iovance Biotherapeutics
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
825 Industrial Rd Ste 400, San Carlos, C...Phone Number
(650) 260-7120Website
www.iovance.comRevenue
$285.6 MillionStock Symbol
IOVAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
2
1
1
1
About Iovance Biotherapeutics
Iovance Biotherapeutics, founded in 2007 and headquartered in San Carlos, California, is a biopharmaceutical company developing tumor-infiltrating lymphocyte therapies against cancer.Explore more
Iovance Biotherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
JC
Senior Vice President, Clinical Science
BP
Senior VP, Manufacturing
ML
Vice President, Drug Safety
AK
Vice President, Quality Control
AP
Vice President
TL
Global Vice President, Commercial Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iovance Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Iovance Biotherapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Iovance Biotherapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Iovance Biotherapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Iovance Biotherapeutics
Check if Iovance Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Iovance Biotherapeutics is spiking on competitors!
Iovance Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Iovance Biotherapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Iovance Biotherapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Iovance Biotherapeutics
Compare insights from companies similar to Iovance Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Iovance Biotherapeutics
$285.6M
501-1,000
Public
$1.1B
2007
FV
Frederick VogtInterim CEO & General Counsel
$236M
501-1,000
Public
$250M
2015
Company Profile Activity
Activity Insights
Iovance Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iovance Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iovance Biotherapeutics.
Iovance Biotherapeutics financials insights
Gather financial insights about Iovance Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Share Placement
$21.6M
2014
Stock Offering
$34.5M
2015
Stock Offering
$73.6M
2016
Share Placement
$100M
2017
Stock Offering
$57.5M
2018
Stock Offering
$172.5M
Stock Offering
$252M
2025
Stock/Share Issuance
$350M
Iovance Biotherapeutics Tech Stack
A closer look at the technologies used by Iovance Biotherapeutics
See more technologies
Most Recent Scoops
Open Position
Person-Based
Stake & Stock Ownership, Pharmaceuticals, Finance
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Iovance Biotherapeutics News & Media
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new,Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001
While Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has gained 54.95% year-to-date, analysts continue to see 112.80% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Two meaningful pipeline and regulatory developments arrived within days of each other, adding fresh momentum to Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s expanding TIL therapy platform. […]Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target. The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iovance Biotherapeutics
Sign Up For FreeTo access detailed company insights
Iovance Biotherapeutics, founded in 2007 and headquartered in San Carlos, California, is a biopharmaceutical company developing tumor-infiltrating lymphocyte therapies against cancer.... Read More
